We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | NASDAQ:HALO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.52 | 1.32% | 39.82 | 37.50 | 42.69 | 40.74 | 38.88 | 39.56 | 832,175 | 00:59:59 |
|
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
September 29, 2017
|
Delaware
|
001-32335
|
|
88-0488686
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
11388 Sorrento Valley Road, San Diego, California
|
92121
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code:
|
|
(858) 794-8889
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Transition Services Agreement and General Release of Claims, effective as of September 29, 2017, and Consulting Agreement, effective as of September 30, 2017
|
|
|
|
|
|
|
|
|
|
HALOZYME THERAPEUTICS, INC.
|
||
|
|
|
|
|
September 29, 2017
|
|
By:
|
|
/s/ Harry J. Leonhardt
|
|
|
Name:
|
|
Harry J. Leonhardt, Esq.
|
|
|
Title:
|
|
Senior Vice President, General Counsel,
Chief Compliance Officer and Corporate Secretary
|
1 Year Halozyme Therapeutics Chart |
1 Month Halozyme Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions